RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00808067
First received: December 12, 2008
Last updated: June 3, 2014
Last verified: March 2014
  Purpose

The purposes of this study are:

  1. To evaluate the long-term safety of dabigatran etexilate
  2. To assess the effect of a knowledge translation intervention on patient outcomes

Condition Intervention Phase
Atrial Fibrillation
Drug: dabigatran dose 1
Drug: dabigatran dose 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Major Bleeding, Annualized Rate of Subjects With Major Bleeds [ Time Frame: up to 43 months ] [ Designated as safety issue: Yes ]

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Major bleeding must have satisfied one or more of the following criteria:

    • Bleeding associated with a reduction in hemoglobin of at least 20 g/L
    • Required transfusion of at least 2 units of blood or packed cells
    • Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal

    Major bleed were classified as life-threatening if they met one or more of the following criteria:

    • Reduction in hemoglobin of at least 50 g/L
    • Transfusion of at least 4 units of blood or packed cells
    • Symptomatic intracranial bleeding, either subdural or intracerebral
    • Associated with hypotension requiring use of intravenous inotropic agents
    • Required surgical intervention to stop bleeding
    • Resulted in death


Secondary Outcome Measures:
  • Stroke, Annualized Rate of Subjects With Stroke [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital


  • Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy.


  • Pulmonary Embolism (PE), Annualized Rate of Subjects With PE [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Pulmonary Embolism was generally documented by one of the following:

    1. an intraluminal filling defect in segmental or more proximal branches on spiral CT scan
    2. an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram
    3. a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)
    4. inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography.

  • Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    a. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy.


  • Deep Vein Thrombosis, Annualized Rate of Subjects With DVT [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Deep Vein Thrombosis (DVT) was generally documented by one of the following:

    1. abnormal compression ultrasound (CUS),
    2. an intraluminal filling defect on venography.

  • Death, Annualized Rate of Subject Death [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology.


  • Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]
    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

  • Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]
    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

  • Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]
    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

  • Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction (MI), All Cause Death and Major Bleed [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]
    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

  • Annualized Rate of Subjects With Minor Bleeds [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not.


  • Annualized Rate of Subjects With Any Bleeds (Major Plus Minor) [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]
    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

  • Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH) [ Time Frame: up to 43 months ] [ Designated as safety issue: No ]
    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.


Enrollment: 5897
Study Start Date: November 2008
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: dabigatran dose 1
dabigatran high dose twice daily
Drug: dabigatran dose 1
dabigatran high dose twice daily
Experimental: dabigatran dose 2
dabigatran low dose twice daily
Drug: dabigatran dose 2
dabigatran low dose twice daily

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Participation in RE-LY, requires long term anticoagulation, provides written informed consent

Exclusion criteria:

Permanent discontinuation of dabigatran during RE-LY

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00808067

  Hide Study Locations
Locations
United States, Alabama
1160.71.0046 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1160.71.0057 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1160.71.0211 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1160.71.0115 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
United States, Arizona
1160.71.0104 Boehringer Ingelheim Investigational Site
Lake Havasu City, Arizona, United States
1160.71.0185 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
United States, Arkansas
1160.71.0038 Boehringer Ingelheim Investigational Site
Hot Springs, Arkansas, United States
1160.71.0302 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas, United States
1160.71.0191 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
1160.71.0213 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
United States, California
1160.71.0441 Boehringer Ingelheim Investigational Site
Carmichael, California, United States
1160.71.0333 Boehringer Ingelheim Investigational Site
Fullerton, California, United States
1160.71.0384 Boehringer Ingelheim Investigational Site
La Jolla, California, United States
1160.71.0246 Boehringer Ingelheim Investigational Site
Lancaster, California, United States
1160.71.0070 Boehringer Ingelheim Investigational Site
Merced, California, United States
1160.71.0349 Boehringer Ingelheim Investigational Site
Oakland, California, United States
1160.71.0016 Boehringer Ingelheim Investigational Site
Oceanside, California, United States
1160.71.0459 Boehringer Ingelheim Investigational Site
Pasadena, California, United States
1160.71.0270 Boehringer Ingelheim Investigational Site
Poway, California, United States
1160.71.0135 Boehringer Ingelheim Investigational Site
Riverside, California, United States
1160.71.0300 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
1160.71.0284 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1160.71.0379 Boehringer Ingelheim Investigational Site
Walnut Creek, California, United States
United States, Colorado
1160.71.0321 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
1160.71.0449 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
1160.71.0413 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1160.71.0360 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1160.71.0362 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado, United States
United States, Connecticut
1160.71.0278 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut, United States
1160.71.0482 Boehringer Ingelheim Investigational Site
Guilford, Connecticut, United States
United States, Florida
1160.71.0382 Boehringer Ingelheim Investigational Site
Boynton Beach, Florida, United States
1160.71.0056 Boehringer Ingelheim Investigational Site
Brandon, Florida, United States
1160.71.0296 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1160.71.0327 Boehringer Ingelheim Investigational Site
Coral Springs, Florida, United States
1160.71.0376 Boehringer Ingelheim Investigational Site
Daytona Beach, Florida, United States
1160.71.0074 Boehringer Ingelheim Investigational Site
Fort Myers, Florida, United States
1160.71.0427 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.71.0089 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.71.0232 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.71.0012 Boehringer Ingelheim Investigational Site
Lakeland, Florida, United States
1160.71.0034 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1160.71.0227 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
1160.71.0095 Boehringer Ingelheim Investigational Site
Ormond Beach, Florida, United States
1160.71.0037 Boehringer Ingelheim Investigational Site
Pensacola, Florida, United States
1160.71.0137 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
1160.71.0417 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
1160.71.0332 Boehringer Ingelheim Investigational Site
Rockledge, Florida, United States
1160.71.0385 Boehringer Ingelheim Investigational Site
Sarasota, Florida, United States
1160.71.0339 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
1160.71.0015 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
1160.71.0019 Boehringer Ingelheim Investigational Site
Vero Beach, Florida, United States
United States, Georgia
1160.71.0159 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1160.71.0021 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
1160.71.0161 Boehringer Ingelheim Investigational Site
Conyers, Georgia, United States
United States, Illinois
1160.71.0218 Boehringer Ingelheim Investigational Site
Cicero, Illinois, United States
1160.71.0438 Boehringer Ingelheim Investigational Site
Maywood, Illinois, United States
1160.71.0331 Boehringer Ingelheim Investigational Site
Melrose Park, Illinois, United States
1160.71.0364 Boehringer Ingelheim Investigational Site
Normal, Illinois, United States
1160.71.0109 Boehringer Ingelheim Investigational Site
North Chicago, Illinois, United States
1160.71.0152 Boehringer Ingelheim Investigational Site
Oak Lawn, Illinois, United States
1160.71.0198 Boehringer Ingelheim Investigational Site
Rockford, Illinois, United States
1160.71.0433 Boehringer Ingelheim Investigational Site
Winfield, Illinois, United States
United States, Indiana
1160.71.0377 Boehringer Ingelheim Investigational Site
Fort Wayne, Indiana, United States
1160.71.0288 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
1160.71.0352 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
1160.71.0436 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
1160.71.0235 Boehringer Ingelheim Investigational Site
South Bend, Indiana, United States
United States, Iowa
1160.71.0268 Boehringer Ingelheim Investigational Site
Dubuque, Iowa, United States
1160.71.0001 Boehringer Ingelheim Investigational Site
West Des Moines, Iowa, United States
1160.71.0357 Boehringer Ingelheim Investigational Site
West Des Moines, Iowa, United States
United States, Kentucky
1160.71.0422 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
1160.71.0178 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
1160.71.0397 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
1160.71.0310 Boehringer Ingelheim Investigational Site
Owensboro, Kentucky, United States
United States, Louisiana
1160.71.0144 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana, United States
1160.71.0018 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana, United States
1160.71.0132 Boehringer Ingelheim Investigational Site
New Iberia, Louisiana, United States
United States, Maine
1160.71.0096 Boehringer Ingelheim Investigational Site
Auburn, Maine, United States
United States, Maryland
1160.71.0114 Boehringer Ingelheim Investigational Site
Annapolis, Maryland, United States
1160.71.0023 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.71.0047 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.71.0186 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.71.0079 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.71.0194 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.71.0255 Boehringer Ingelheim Investigational Site
Bel Air, Maryland, United States
1160.71.0398 Boehringer Ingelheim Investigational Site
Columbia, Maryland, United States
1160.71.0177 Boehringer Ingelheim Investigational Site
Rockville, Maryland, United States
1160.71.0207 Boehringer Ingelheim Investigational Site
Salisbury, Maryland, United States
1160.71.0073 Boehringer Ingelheim Investigational Site
Salisbury, Maryland, United States
1160.71.0196 Boehringer Ingelheim Investigational Site
Takoma Park, Maryland, United States
1160.71.0187 Boehringer Ingelheim Investigational Site
Towson, Maryland, United States
1160.71.0052 Boehringer Ingelheim Investigational Site
Westminster, Maryland, United States
United States, Massachusetts
1160.71.0452 Boehringer Ingelheim Investigational Site
Haverhill, Massachusetts, United States
1160.71.0443 Boehringer Ingelheim Investigational Site
Haverhill, Massachusetts, United States
1160.71.0029 Boehringer Ingelheim Investigational Site
Natick, Massachusetts, United States
1160.71.0003 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts, United States
1160.71.0308 Boehringer Ingelheim Investigational Site
Worcester, Massachusetts, United States
United States, Michigan
1160.71.0154 Boehringer Ingelheim Investigational Site
Grand Blanc, Michigan, United States
1160.71.0205 Boehringer Ingelheim Investigational Site
Lapeer, Michigan, United States
1160.71.0279 Boehringer Ingelheim Investigational Site
Muskegon, Michigan, United States
1160.71.0445 Boehringer Ingelheim Investigational Site
Petoskey, Michigan, United States
1160.71.0274 Boehringer Ingelheim Investigational Site
Rochester Hills, Michigan, United States
1160.71.0165 Boehringer Ingelheim Investigational Site
Saginaw, Michigan, United States
1160.71.0020 Boehringer Ingelheim Investigational Site
Troy, Michigan, United States
1160.71.0188 Boehringer Ingelheim Investigational Site
Ypsilanti, Michigan, United States
United States, Minnesota
1160.71.0202 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
1160.71.0101 Boehringer Ingelheim Investigational Site
St. Paul, Minnesota, United States
United States, Mississippi
1160.71.0086 Boehringer Ingelheim Investigational Site
Gulfport, Mississippi, United States
1160.71.0119 Boehringer Ingelheim Investigational Site
Tupelo, Mississippi, United States
United States, Missouri
1160.71.0055 Boehringer Ingelheim Investigational Site
Columbia, Missouri, United States
1160.71.0257 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
1160.71.0336 Boehringer Ingelheim Investigational Site
St. Charles, Missouri, United States
1160.71.0249 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, Montana
1160.71.0027 Boehringer Ingelheim Investigational Site
Kalispell, Montana, United States
United States, Nebraska
1160.71.0110 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, Nevada
1160.71.0346 Boehringer Ingelheim Investigational Site
Henderson, Nevada, United States
1160.71.0430 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
United States, New Jersey
1160.71.0142 Boehringer Ingelheim Investigational Site
Browns Mills, New Jersey, United States
1160.71.0221 Boehringer Ingelheim Investigational Site
Cherry Hill, New Jersey, United States
1160.71.0248 Boehringer Ingelheim Investigational Site
Flemington, New Jersey, United States
1160.71.0478 Boehringer Ingelheim Investigational Site
Oakland, New Jersey, United States
1160.71.0392 Boehringer Ingelheim Investigational Site
Ocean, New Jersey, United States
1160.71.0254 Boehringer Ingelheim Investigational Site
Westwood, New Jersey, United States
1160.71.0472 Boehringer Ingelheim Investigational Site
Woodland Park, New Jersey, United States
United States, New York
1160.71.0476 Boehringer Ingelheim Investigational Site
Albany, New York, United States
1160.71.0281 Boehringer Ingelheim Investigational Site
Bronx, New York, United States
1160.71.0113 Boehringer Ingelheim Investigational Site
Bronx, New York, United States
1160.71.0044 Boehringer Ingelheim Investigational Site
Cortlandt Manor, New York, United States
1160.71.0229 Boehringer Ingelheim Investigational Site
Mineola, New York, United States
1160.71.0451 Boehringer Ingelheim Investigational Site
Mineola, New York, United States
1160.71.0183 Boehringer Ingelheim Investigational Site
New Rochelle, New York, United States
1160.71.0210 Boehringer Ingelheim Investigational Site
Northport, New York, United States
1160.71.0075 Boehringer Ingelheim Investigational Site
Poughkeepsie, New York, United States
1160.71.0414 Boehringer Ingelheim Investigational Site
Troy, New York, United States
1160.71.0356 Boehringer Ingelheim Investigational Site
Watertown, New York, United States
1160.71.0064 Boehringer Ingelheim Investigational Site
Yonkers, New York, United States
United States, North Carolina
1160.71.0353 Boehringer Ingelheim Investigational Site
Asheville, North Carolina, United States
1160.71.0080 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
1160.71.0350 Boehringer Ingelheim Investigational Site
Gastonia, North Carolina, United States
1160.71.0173 Boehringer Ingelheim Investigational Site
High Point, North Carolina, United States
1160.71.0006 Boehringer Ingelheim Investigational Site
Pinehurst, North Carolina, United States
1160.71.0069 Boehringer Ingelheim Investigational Site
Statesville, North Carolina, United States
1160.71.0002 Boehringer Ingelheim Investigational Site
Statesville, North Carolina, United States
United States, North Dakota
1160.71.0102 Boehringer Ingelheim Investigational Site
Grand Forks, North Dakota, United States
1160.71.0222 Boehringer Ingelheim Investigational Site
Jamestown, North Dakota, United States
United States, Ohio
1160.71.0203 Boehringer Ingelheim Investigational Site
Akron, Ohio, United States
1160.71.0434 Boehringer Ingelheim Investigational Site
Canal Fulton, Ohio, United States
1160.71.0426 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1160.71.0402 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1160.71.0479 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1160.71.0480 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
1160.71.0263 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
1160.71.0267 Boehringer Ingelheim Investigational Site
Columbus, Ohio, United States
1160.71.0035 Boehringer Ingelheim Investigational Site
Dayton, Ohio, United States
1160.71.0150 Boehringer Ingelheim Investigational Site
Fairview Park, Ohio, United States
1160.71.0201 Boehringer Ingelheim Investigational Site
Kettering, Ohio, United States
1160.71.0223 Boehringer Ingelheim Investigational Site
Lorain, Ohio, United States
1160.71.0214 Boehringer Ingelheim Investigational Site
Lyndhurst, Ohio, United States
1160.71.0275 Boehringer Ingelheim Investigational Site
Sandusky, Ohio, United States
1160.71.0103 Boehringer Ingelheim Investigational Site
Westlake, Ohio, United States
United States, Oklahoma
1160.71.0435 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma, United States
United States, Oregon
1160.71.0139 Boehringer Ingelheim Investigational Site
Corvallis, Oregon, United States
1160.71.0325 Boehringer Ingelheim Investigational Site
Eugene, Oregon, United States
1160.71.0133 Boehringer Ingelheim Investigational Site
Springfield, Oregon, United States
United States, Pennsylvania
1160.71.0301 Boehringer Ingelheim Investigational Site
Allentown, Pennsylvania, United States
1160.71.0295 Boehringer Ingelheim Investigational Site
Camp Hill, Pennsylvania, United States
1160.71.0294 Boehringer Ingelheim Investigational Site
Hershey, Pennsylvania, United States
1160.71.0369 Boehringer Ingelheim Investigational Site
Jenkintown, Pennsylvania, United States
1160.71.0431 Boehringer Ingelheim Investigational Site
Lancaster, Pennsylvania, United States
1160.71.0168 Boehringer Ingelheim Investigational Site
Langhorne, Pennsylvania, United States
1160.71.0293 Boehringer Ingelheim Investigational Site
Meadowbrook, Pennsylvania, United States
1160.71.0394 Boehringer Ingelheim Investigational Site
Norristown, Pennsylvania, United States
1160.71.0466 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
1160.71.0208 Boehringer Ingelheim Investigational Site
Sellersville, Pennsylvania, United States
1160.71.0465 Boehringer Ingelheim Investigational Site
Uniontown, Pennsylvania, United States
1160.71.0032 Boehringer Ingelheim Investigational Site
Wynnewood, Pennsylvania, United States
1160.71.0067 Boehringer Ingelheim Investigational Site
Wyomissing, Pennsylvania, United States
United States, South Carolina
1160.71.0007 Boehringer Ingelheim Investigational Site
Beaufort, South Carolina, United States
1160.71.0383 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1160.71.0313 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
1160.71.0166 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina, United States
1160.71.0008 Boehringer Ingelheim Investigational Site
Summerville, South Carolina, United States
United States, Tennessee
1160.71.0084 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
1160.71.0474 Boehringer Ingelheim Investigational Site
Clinton, Tennessee, United States
1160.71.0062 Boehringer Ingelheim Investigational Site
Germantown, Tennessee, United States
1160.71.0370 Boehringer Ingelheim Investigational Site
Johnson City, Tennessee, United States
1160.71.0395 Boehringer Ingelheim Investigational Site
Nashville, Tennessee, United States
United States, Texas
1160.71.0410 Boehringer Ingelheim Investigational Site
Austin, Texas, United States
1160.71.0129 Boehringer Ingelheim Investigational Site
Austin, Texas, United States
1160.71.0156 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1160.71.0315 Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
1160.71.0447 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1160.71.0483 Boehringer Ingelheim Investigational Site
Killeen, Texas, United States
1160.71.0335 Boehringer Ingelheim Investigational Site
Lubbock, Texas, United States
1160.71.0307 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1160.71.0269 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1160.71.0285 Boehringer Ingelheim Investigational Site
San Marcos, Texas, United States
1160.71.0367 Boehringer Ingelheim Investigational Site
Tyler, Texas, United States
United States, Virginia
1160.71.0453 Boehringer Ingelheim Investigational Site
Charlottesville, Virginia, United States
1160.71.0053 Boehringer Ingelheim Investigational Site
Chesapeake, Virginia, United States
1160.71.0428 Boehringer Ingelheim Investigational Site
Fredericksburg, Virginia, United States
1160.71.0311 Boehringer Ingelheim Investigational Site
Harrisonburg, Virginia, United States
1160.71.0292 Boehringer Ingelheim Investigational Site
Newport News, Virginia, United States
1160.71.0220 Boehringer Ingelheim Investigational Site
Salem, Virginia, United States
1160.71.0224 Boehringer Ingelheim Investigational Site
Suffolk, Virginia, United States
1160.71.0317 Boehringer Ingelheim Investigational Site
Winchester, Virginia, United States
United States, Washington
1160.71.0050 Boehringer Ingelheim Investigational Site
Bellingham, Washington, United States
1160.71.0040 Boehringer Ingelheim Investigational Site
Burien, Washington, United States
1160.71.0250 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
1160.71.0256 Boehringer Ingelheim Investigational Site
Tacoma, Washington, United States
1160.71.0024 Boehringer Ingelheim Investigational Site
Wenatchee, Washington, United States
United States, West Virginia
1160.71.0169 Boehringer Ingelheim Investigational Site
Clarksburg, West Virginia, United States
1160.71.0365 Boehringer Ingelheim Investigational Site
Huntington, West Virginia, United States
United States, Wisconsin
1160.71.0099 Boehringer Ingelheim Investigational Site
Madison, Wisconsin, United States
1160.71.0072 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin, United States
1160.71.0461 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin, United States
Australia, New South Wales
1160.71.0508 Boehringer Ingelheim Investigational Site
Coffs Harbour, New South Wales, Australia
1160.71.0510 Boehringer Ingelheim Investigational Site
Gosford, New South Wales, Australia
Australia, Queensland
1160.71.0506 Boehringer Ingelheim Investigational Site
Milton, Queensland, Australia
Australia, South Australia
1160.71.0509 Boehringer Ingelheim Investigational Site
Ashford, South Australia, Australia
Australia, Tasmania
1160.71.0507 Boehringer Ingelheim Investigational Site
Launceston, Tasmania, Australia
Australia, Victoria
1160.71.0504 Boehringer Ingelheim Investigational Site
Box Hill, Victoria, Australia
1160.71.0501 Boehringer Ingelheim Investigational Site
Geelong, Victoria, Australia
Austria
1160.71.0543 Boehringer Ingelheim Investigational Site
Graz, Austria
1160.71.0549 Boehringer Ingelheim Investigational Site
Linz, Austria
1160.71.0542 Boehringer Ingelheim Investigational Site
Wien, Austria
1160.71.0545 Boehringer Ingelheim Investigational Site
Wien, Austria
1160.71.0547 Boehringer Ingelheim Investigational Site
Wien, Austria
1160.71.0541 Boehringer Ingelheim Investigational Site
Wien, Austria
1160.71.0548 Boehringer Ingelheim Investigational Site
Wien, Austria
1160.71.0550 Boehringer Ingelheim Investigational Site
Wr. Neustadt, Austria
Belgium
1160.71.0564 Boehringer Ingelheim Investigational Site
Aalst, Belgium
1160.71.0572 Boehringer Ingelheim Investigational Site
Brasschaat, Belgium
1160.71.0571 Boehringer Ingelheim Investigational Site
Brussel, Belgium
1160.71.0585 Boehringer Ingelheim Investigational Site
Bruxelles, Belgium
1160.71.0581 Boehringer Ingelheim Investigational Site
Bruxelles, Belgium
1160.71.0563 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1160.71.0587 Boehringer Ingelheim Investigational Site
Genk, Belgium
1160.71.0578 Boehringer Ingelheim Investigational Site
Genk, Belgium
1160.71.0574 Boehringer Ingelheim Investigational Site
Gent, Belgium
1160.71.0588 Boehringer Ingelheim Investigational Site
Gilly, Belgium
1160.71.0568 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
1160.71.0561 Boehringer Ingelheim Investigational Site
Leuven, Belgium
1160.71.0579 Boehringer Ingelheim Investigational Site
Liège, Belgium
1160.71.0567 Boehringer Ingelheim Investigational Site
Oostende, Belgium
1160.71.0570 Boehringer Ingelheim Investigational Site
Roeselare, Belgium
1160.71.0566 Boehringer Ingelheim Investigational Site
Tienen, Belgium
1160.71.0562 Boehringer Ingelheim Investigational Site
Turnhout, Belgium
Brazil
1160.71.0644 Boehringer Ingelheim Investigational Site
Campinas, Brazil
1160.71.0650 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1160.71.0651 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1160.71.0652 Boehringer Ingelheim Investigational Site
Goiania, Brazil
1160.71.0646 Boehringer Ingelheim Investigational Site
Sao Jose do Riio Preto, Brazil
1160.71.0647 Boehringer Ingelheim Investigational Site
São José do Rio Preto, Brazil
1160.71.0643 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
Bulgaria
1160.71.0620 Boehringer Ingelheim Investigational Site
Pleven, Bulgaria
1160.71.0618 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1160.71.0611 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1160.71.0617 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1160.71.0612 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1160.71.0615 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1160.71.0625 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
Canada, Alberta
1160.71.0694 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1160.71.0696 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
Canada, British Columbia
1160.71.0680 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia, Canada
1160.71.0712 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia, Canada
1160.71.0706 Boehringer Ingelheim Investigational Site
Kelowna, British Columbia, Canada
1160.71.0725 Boehringer Ingelheim Investigational Site
Nanaimo, British Columbia, Canada
1160.71.0691 Boehringer Ingelheim Investigational Site
New Westminster, British Columbia, Canada
1160.71.0714 Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
Canada, Manitoba
1160.71.0701 Boehringer Ingelheim Investigational Site
Portage la Prairie, Manitoba, Canada
Canada, Nova Scotia
1160.71.0703 Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia, Canada
Canada, Ontario
1160.71.0674 Boehringer Ingelheim Investigational Site
Burlington, Ontario, Canada
1160.71.0720 Boehringer Ingelheim Investigational Site
Cambridge, Ontario, Canada
1160.71.0702 Boehringer Ingelheim Investigational Site
Cambridge, Ontario, Canada
1160.71.0692 Boehringer Ingelheim Investigational Site
Grimsby, Ontario, Canada
1160.71.0721 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.71.0719 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.71.0697 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.71.0710 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.71.0708 Boehringer Ingelheim Investigational Site
Mississauga, Ontario, Canada
1160.71.0688 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1160.71.0672 Boehringer Ingelheim Investigational Site
Oshawa, Ontario, Canada
1160.71.0687 Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
1160.71.0723 Boehringer Ingelheim Investigational Site
Scarborough, Ontario, Canada
1160.71.0679 Boehringer Ingelheim Investigational Site
Scarborough, Ontario, Canada
1160.71.0715 Boehringer Ingelheim Investigational Site
Sudbury, Ontario, Canada
1160.71.0690 Boehringer Ingelheim Investigational Site
Thunder Bay, Ontario, Canada
1160.71.0684 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1160.71.0718 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1160.71.0686 Boehringer Ingelheim Investigational Site
Windsor, Ontario, Canada
Canada, Quebec
1160.71.0705 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.71.0683 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.71.0716 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.71.0709 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.71.0717 Boehringer Ingelheim Investigational Site
Quebec City, Quebec, Canada
1160.71.0699 Boehringer Ingelheim Investigational Site
St. Charles-Borromee, Quebec, Canada
1160.71.0713 Boehringer Ingelheim Investigational Site
St. George-de-Beauce, Quebec, Canada
1160.71.0675 Boehringer Ingelheim Investigational Site
St. Hyacinthe, Quebec, Canada
Canada, Saskatchewan
1160.71.0678 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
1160.71.0673 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
Canada
1160.71.0700 Boehringer Ingelheim Investigational Site
Quebec, Canada
China
1160.71.0771 Boehringer Ingelheim Investigational Site
Beijing, China
1160.71.0772 Boehringer Ingelheim Investigational Site
Beijing, China
1160.71.0773 Boehringer Ingelheim Investigational Site
Beijing, China
1160.71.0774 Boehringer Ingelheim Investigational Site
Beijing, China
1160.71.0776 Boehringer Ingelheim Investigational Site
Haerbin, China
1160.71.0784 Boehringer Ingelheim Investigational Site
Hangzhou, China
1160.71.0778 Boehringer Ingelheim Investigational Site
QingDao, China
1160.71.0781 Boehringer Ingelheim Investigational Site
Shanghai, China
1160.71.0782 Boehringer Ingelheim Investigational Site
Shanghai, China
1160.71.0777 Boehringer Ingelheim Investigational Site
Shenyang, China
1160.71.0780 Boehringer Ingelheim Investigational Site
Shijiazhuang, China
Czech Republic
1160.71.0816 Boehringer Ingelheim Investigational Site
Modrice, Czech Republic
1160.71.0820 Boehringer Ingelheim Investigational Site
Ostrava 1, Czech Republic
1160.71.0818 Boehringer Ingelheim Investigational Site
Pardubice, Czech Republic
1160.71.0814 Boehringer Ingelheim Investigational Site
Plzen-Bory, Czech Republic
1160.71.0811 Boehringer Ingelheim Investigational Site
Praha 5, Czech Republic
1160.71.0812 Boehringer Ingelheim Investigational Site
Praha 6, Czech Republic
1160.71.0813 Boehringer Ingelheim Investigational Site
Praha 9, Czech Republic
1160.71.0817 Boehringer Ingelheim Investigational Site
Pribram, Czech Republic
1160.71.0819 Boehringer Ingelheim Investigational Site
Usti nad Orlici, Czech Republic
Denmark
1160.71.0837 Boehringer Ingelheim Investigational Site
Aalborg, Denmark
1160.71.0835 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
1160.71.0838 Boehringer Ingelheim Investigational Site
Frederikssund, Denmark
1160.71.0833 Boehringer Ingelheim Investigational Site
Helsingør, Denmark
1160.71.0834 Boehringer Ingelheim Investigational Site
Herlev, Denmark
1160.71.0841 Boehringer Ingelheim Investigational Site
Horsens, Denmark
1160.71.0832 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
1160.71.0840 Boehringer Ingelheim Investigational Site
Køge, Denmark
1160.71.0831 Boehringer Ingelheim Investigational Site
Odense, Denmark
1160.71.0839 Boehringer Ingelheim Investigational Site
Roskilde, Denmark
1160.71.0836 Boehringer Ingelheim Investigational Site
Svendborg, Denmark
Finland
1160.71.0851 Boehringer Ingelheim Investigational Site
Helsinki, Finland
1160.71.0859 Boehringer Ingelheim Investigational Site
Jyväskylä, Finland
1160.71.0854 Boehringer Ingelheim Investigational Site
Oulu, Finland
1160.71.0858 Boehringer Ingelheim Investigational Site
Pori, Finland
1160.71.0852 Boehringer Ingelheim Investigational Site
Tampere, Finland
1160.71.0853 Boehringer Ingelheim Investigational Site
Turku, Finland
France
1160.71.875A Boehringer Ingelheim Investigational Site
ABBEVILLE cedex, France
1160.71.882G Boehringer Ingelheim Investigational Site
Angers, France
1160.71.882D Boehringer Ingelheim Investigational Site
Angers, France
1160.71.879F Boehringer Ingelheim Investigational Site
Besle Sur Vilaine, France
1160.71.887A Boehringer Ingelheim Investigational Site
Cholet, France
1160.71.882K Boehringer Ingelheim Investigational Site
Château Gontier, France
1160.71.879C Boehringer Ingelheim Investigational Site
Derval, France
1160.71.882H Boehringer Ingelheim Investigational Site
Feneu, France
1160.71.888A Boehringer Ingelheim Investigational Site
GRENOBLE Cédex 9, France
1160.71.879B Boehringer Ingelheim Investigational Site
La Chapelle sur Erdre, France
1160.71.874A Boehringer Ingelheim Investigational Site
Langres, France
1160.71.884A Boehringer Ingelheim Investigational Site
Laval, France
1160.71.880B Boehringer Ingelheim Investigational Site
Le Mesnil en Valée, France
1160.71.880A Boehringer Ingelheim Investigational Site
Murs Erigne, France
1160.71.879A Boehringer Ingelheim Investigational Site
Nantes, France
1160.71.879S Boehringer Ingelheim Investigational Site
Nantes, France
1160.71.879H Boehringer Ingelheim Investigational Site
Nantes, France
1160.71.880J Boehringer Ingelheim Investigational Site
Parcay les Pins, France
1160.71.871A Boehringer Ingelheim Investigational Site
Paris, France
1160.71.879E Boehringer Ingelheim Investigational Site
Saint Aubin Des Chateaux, France
1160.71.880D Boehringer Ingelheim Investigational Site
Segre, France
1160.71.882A Boehringer Ingelheim Investigational Site
Tierce, France
1160.71.882C Boehringer Ingelheim Investigational Site
Tierce, France
1160.71.882B Boehringer Ingelheim Investigational Site
Tierce, France
1160.71.879G Boehringer Ingelheim Investigational Site
Vieillevigne, France
1160.71.880E Boehringer Ingelheim Investigational Site
Vihiers, France
Germany
1160.71.0962 Boehringer Ingelheim Investigational Site
Berlin, Germany
1160.71.0932 Boehringer Ingelheim Investigational Site
Berlin, Germany
1160.71.0948 Boehringer Ingelheim Investigational Site
Berlin, Germany
1160.71.0940 Boehringer Ingelheim Investigational Site
Bochum, Germany
1160.71.0972 Boehringer Ingelheim Investigational Site
Dortmund, Germany
1160.71.0934 Boehringer Ingelheim Investigational Site
Essen, Germany
1160.71.0931 Boehringer Ingelheim Investigational Site
Frankfurt am Main, Germany
1160.71.0943 Boehringer Ingelheim Investigational Site
Heidelberg, Germany
1160.71.0963 Boehringer Ingelheim Investigational Site
Köln, Germany
1160.71.0946 Boehringer Ingelheim Investigational Site
Lahr, Germany
1160.71.0944 Boehringer Ingelheim Investigational Site
Limburg, Germany
1160.71.0951 Boehringer Ingelheim Investigational Site
Mainz, Germany
1160.71.0933 Boehringer Ingelheim Investigational Site
Mannheim, Germany
1160.71.0945 Boehringer Ingelheim Investigational Site
Mannheim, Germany
1160.71.0970 Boehringer Ingelheim Investigational Site
Mannheim, Germany
1160.71.0937 Boehringer Ingelheim Investigational Site
Witten, Germany
1160.71.0966 Boehringer Ingelheim Investigational Site
Wuppertal, Germany
Greece
1160.71.0901 Boehringer Ingelheim Investigational Site
Athens, Greece
1160.71.0914 Boehringer Ingelheim Investigational Site
Kalamaria-Thessaloniki, Greece
1160.71.0904 Boehringer Ingelheim Investigational Site
Larissa, Greece
1160.71.0910 Boehringer Ingelheim Investigational Site
Thiva, Greece
1160.71.0903 Boehringer Ingelheim Investigational Site
Trikala, Greece
1160.71.0905 Boehringer Ingelheim Investigational Site
Voula - Athens, Greece
Hong Kong
1160.71.1003 Boehringer Ingelheim Investigational Site
Kowloon, Hong Kong
1160.71.1004 Boehringer Ingelheim Investigational Site
Kowloon, Hong Kong
Hungary
1160.71.1011 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1160.71.1012 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1160.71.1013 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1160.71.1016 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1160.71.1015 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1160.71.1014 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1160.71.1020 Boehringer Ingelheim Investigational Site
Gyongyos, Hungary
1160.71.1017 Boehringer Ingelheim Investigational Site
Komarom, Hungary
1160.71.1018 Boehringer Ingelheim Investigational Site
Pecs, Hungary
India
1160.71.1057 Boehringer Ingelheim Investigational Site
Ahmedabad, India
1160.71.1056 Boehringer Ingelheim Investigational Site
Ahmedabad-52, India
1160.71.1065 Boehringer Ingelheim Investigational Site
Bangalore, India
1160.71.1062 Boehringer Ingelheim Investigational Site
Hyderabad, India
1160.71.1073 Boehringer Ingelheim Investigational Site
Jaipur, Rajasthan, India
1160.71.1067 Boehringer Ingelheim Investigational Site
Kerala, India
1160.71.1068 Boehringer Ingelheim Investigational Site
Kottayam, India
1160.71.1055 Boehringer Ingelheim Investigational Site
Lucknow, Uttar Pradesh, India
1160.71.1051 Boehringer Ingelheim Investigational Site
Ludhiana, India
1160.71.1072 Boehringer Ingelheim Investigational Site
Mysore, India
1160.71.1059 Boehringer Ingelheim Investigational Site
Nagpur-12, India
1160.71.1052 Boehringer Ingelheim Investigational Site
New Delhi, India
1160.71.1070 Boehringer Ingelheim Investigational Site
Pune, Maharashtra, India
Israel
1160.71.1110 Boehringer Ingelheim Investigational Site
Afula, Israel
1160.71.1121 Boehringer Ingelheim Investigational Site
Afula, Israel
1160.71.1111 Boehringer Ingelheim Investigational Site
Ashkelon, Israel
1160.71.1117 Boehringer Ingelheim Investigational Site
Givatayim, Israel
1160.71.1112 Boehringer Ingelheim Investigational Site
Hadera, Israel
1160.71.1113 Boehringer Ingelheim Investigational Site
Haifa, Israel
1160.71.1091 Boehringer Ingelheim Investigational Site
Haifa, Israel
1160.71.1118 Boehringer Ingelheim Investigational Site
Haifa, Israel
1160.71.1116 Boehringer Ingelheim Investigational Site
Haifa, Israel
1160.71.1114 Boehringer Ingelheim Investigational Site
Haifa, Israel
1160.71.1105 Boehringer Ingelheim Investigational Site
Holon, Israel
1160.71.1106 Boehringer Ingelheim Investigational Site
Jerusalem, Israel
1160.71.1104 Boehringer Ingelheim Investigational Site
Jerusalem, Israel
1160.71.1101 Boehringer Ingelheim Investigational Site
Jerusalem, Israel
1160.71.1119 Boehringer Ingelheim Investigational Site
Kfar Saba, Israel
1160.71.1096 Boehringer Ingelheim Investigational Site
Petah Tikva, Israel
1160.71.1095 Boehringer Ingelheim Investigational Site
Ramat Gan, Israel
1160.71.1094 Boehringer Ingelheim Investigational Site
Ramat Gan, Israel
1160.71.1093 Boehringer Ingelheim Investigational Site
Ramat Gan, Israel
1160.71.1100 Boehringer Ingelheim Investigational Site
Rehovot, Israel
1160.71.1103 Boehringer Ingelheim Investigational Site
Safed, Israel
1160.71.1122 Boehringer Ingelheim Investigational Site
Tel Aviv, Israel
1160.71.1120 Boehringer Ingelheim Investigational Site
Tel Aviv, Israel
1160.71.1107 Boehringer Ingelheim Investigational Site
Tel-Aviv, Israel
1160.71.1109 Boehringer Ingelheim Investigational Site
Tel-Aviv, Israel
1160.71.1108 Boehringer Ingelheim Investigational Site
Tel-Aviv, Israel
Italy
1160.71.1169 Boehringer Ingelheim Investigational Site
Arezzo, Italy
1160.71.1172 Boehringer Ingelheim Investigational Site
Ascoli Piceno, Italy
1160.71.1170 Boehringer Ingelheim Investigational Site
Sassari, Italy
Korea, Republic of
1160.71.1585 Boehringer Ingelheim Investigational Site
Busan, Korea, Republic of
1160.71.1586 Boehringer Ingelheim Investigational Site
Cheonan-si, Korea, Republic of
1160.71.1584 Boehringer Ingelheim Investigational Site
Daegu, Korea, Republic of
1160.71.1591 Boehringer Ingelheim Investigational Site
Daegu, Korea, Republic of
1160.71.1590 Boehringer Ingelheim Investigational Site
Gwangju, Korea, Republic of
1160.71.1581 Boehringer Ingelheim Investigational Site
Incheon, Korea, Republic of
1160.71.1582 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1160.71.1593 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1160.71.1583 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1160.71.1592 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1160.71.1589 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
Malaysia
1160.71.1291 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
1160.71.1292 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
Netherlands
1160.71.1337 Boehringer Ingelheim Investigational Site
's Hertogenbosch, Netherlands
1160.71.1344 Boehringer Ingelheim Investigational Site
Almelo, Netherlands
1160.71.1331 Boehringer Ingelheim Investigational Site
Amsterdam, Netherlands
1160.71.1336 Boehringer Ingelheim Investigational Site
Apeldoorn, Netherlands
1160.71.1332 Boehringer Ingelheim Investigational Site
Breda, Netherlands
1160.71.1349 Boehringer Ingelheim Investigational Site
Den Helder, Netherlands
1160.71.1345 Boehringer Ingelheim Investigational Site
Deventer, Netherlands
1160.71.1360 Boehringer Ingelheim Investigational Site
Dirksland, Netherlands
1160.71.1340 Boehringer Ingelheim Investigational Site
Ede, Netherlands
1160.71.1358 Boehringer Ingelheim Investigational Site
Eindhoven, Netherlands
1160.71.1338 Boehringer Ingelheim Investigational Site
Enschede, Netherlands
1160.71.1343 Boehringer Ingelheim Investigational Site
Goes, Netherlands
1160.71.1347 Boehringer Ingelheim Investigational Site
Gorinchem, Netherlands
1160.71.1333 Boehringer Ingelheim Investigational Site
Groningen, Netherlands
1160.71.1361 Boehringer Ingelheim Investigational Site
Heerlen, Netherlands
1160.71.1339 Boehringer Ingelheim Investigational Site
Hengelo, Netherlands
1160.71.1346 Boehringer Ingelheim Investigational Site
Hilversum, Netherlands
1160.71.1356 Boehringer Ingelheim Investigational Site
Hoorn, Netherlands
1160.71.1359 Boehringer Ingelheim Investigational Site
Maastricht, Netherlands
1160.71.1341 Boehringer Ingelheim Investigational Site
Meppel, Netherlands
1160.71.1354 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1160.71.1351 Boehringer Ingelheim Investigational Site
Sneek, Netherlands
1160.71.1353 Boehringer Ingelheim Investigational Site
Tiel, Netherlands
1160.71.1352 Boehringer Ingelheim Investigational Site
Tilburg, Netherlands
1160.71.1350 Boehringer Ingelheim Investigational Site
Veldhoven, Netherlands
1160.71.1342 Boehringer Ingelheim Investigational Site
Velp, Netherlands
1160.71.1348 Boehringer Ingelheim Investigational Site
Zwijndrecht, Netherlands
Norway
1160.71.1396 Boehringer Ingelheim Investigational Site
Gjøvik, Norway
1160.71.1393 Boehringer Ingelheim Investigational Site
Moss, Norway
1160.71.1395 Boehringer Ingelheim Investigational Site
Nordbyhagen, Norway
1160.71.1391 Boehringer Ingelheim Investigational Site
Oslo, Norway
1160.71.1397 Boehringer Ingelheim Investigational Site
Oslo, Norway
1160.71.1394 Boehringer Ingelheim Investigational Site
RUD, Norway
Philippines
1160.71.1422 Boehringer Ingelheim Investigational Site
Ermita Manila, Philippines
1160.71.1421 Boehringer Ingelheim Investigational Site
Manila, Philippines
1160.71.1424 Boehringer Ingelheim Investigational Site
Pasig City, Philippines
1160.71.1423 Boehringer Ingelheim Investigational Site
Quezon City, Philippines
1160.71.1425 Boehringer Ingelheim Investigational Site
Quezon City, Philippines
Poland
1160.71.1436 Boehringer Ingelheim Investigational Site
Gdynia, Poland
1160.71.1438 Boehringer Ingelheim Investigational Site
Gdynia, Poland
1160.71.1437 Boehringer Ingelheim Investigational Site
Gdynia, Poland
1160.71.1433 Boehringer Ingelheim Investigational Site
Pulawy, Poland
1160.71.1431 Boehringer Ingelheim Investigational Site
Warsaw, Poland
1160.71.1432 Boehringer Ingelheim Investigational Site
Warsaw, Poland
1160.71.1434 Boehringer Ingelheim Investigational Site
Zabrze, Poland
Portugal
1160.71.1456 Boehringer Ingelheim Investigational Site
Amadora, Portugal
1160.71.1451 Boehringer Ingelheim Investigational Site
Carnaxide, Portugal
1160.71.1454 Boehringer Ingelheim Investigational Site
Coimbra, Portugal
1160.71.1459 Boehringer Ingelheim Investigational Site
Coimbra, Portugal
1160.71.1457 Boehringer Ingelheim Investigational Site
Covilhã, Portugal
1160.71.1455 Boehringer Ingelheim Investigational Site
Porto, Portugal
Romania
1160.71.1471 Boehringer Ingelheim Investigational Site
Bucharest, Romania
1160.71.1472 Boehringer Ingelheim Investigational Site
Bucharest, Romania
Russian Federation
1160.71.1509 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1503 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1504 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1505 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1510 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1508 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1501 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1507 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1511 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1160.71.1512 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1160.71.1513 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1160.71.1514 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
Singapore
1160.71.1531 Boehringer Ingelheim Investigational Site
Singapore, Singapore
Slovakia
1160.71.1548 Boehringer Ingelheim Investigational Site
Banska Bystrica, Slovakia
1160.71.1541 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
1160.71.1542 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
1160.71.1543 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
1160.71.1550 Boehringer Ingelheim Investigational Site
Kosice, Slovakia
1160.71.1547 Boehringer Ingelheim Investigational Site
Zilina, Slovakia
Sweden
1160.71.1633 Boehringer Ingelheim Investigational Site
Göteborg, Sweden
1160.71.1627 Boehringer Ingelheim Investigational Site
Malmö, Sweden
1160.71.1625 Boehringer Ingelheim Investigational Site
Norrköping, Sweden
1160.71.1628 Boehringer Ingelheim Investigational Site
Nässjö, Sweden
1160.71.1634 Boehringer Ingelheim Investigational Site
Stockholm, Sweden
1160.71.1626 Boehringer Ingelheim Investigational Site
Stockholm, Sweden
1160.71.1624 Boehringer Ingelheim Investigational Site
Umeå, Sweden
1160.71.1635 Boehringer Ingelheim Investigational Site
Uppsala, Sweden
1160.71.1621 Boehringer Ingelheim Investigational Site
Uppsala, Sweden
1160.71.1622 Boehringer Ingelheim Investigational Site
Västerås, Sweden
1160.71.1623 Boehringer Ingelheim Investigational Site
Örebro, Sweden
Switzerland
1160.71.1652 Boehringer Ingelheim Investigational Site
Basel, Switzerland
1160.71.1655 Boehringer Ingelheim Investigational Site
Bellinzona, Switzerland
1160.71.1651 Boehringer Ingelheim Investigational Site
Bern, Switzerland
1160.71.1654 Boehringer Ingelheim Investigational Site
Lugano, Switzerland
Taiwan
1160.71.1680 Boehringer Ingelheim Investigational Site
Changhua, Taiwan
1160.71.1683 Boehringer Ingelheim Investigational Site
Hualien, Taiwan
1160.71.1682 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1160.71.1679 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1160.71.1681 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
1160.71.1673 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1160.71.1677 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1160.71.1672 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1160.71.1676 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1160.71.1674 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1160.71.1675 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1160.71.1671 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1160.71.1678 Boehringer Ingelheim Investigational Site
Taoyuan, Taiwan
Thailand
1160.71.1701 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
1160.71.1703 Boehringer Ingelheim Investigational Site
Chiang Mai, Thailand
1160.71.1704 Boehringer Ingelheim Investigational Site
Khon Kaen, Thailand
United Kingdom
1160.71.1744 Boehringer Ingelheim Investigational Site
Birmingham, United Kingdom
1160.71.1746 Boehringer Ingelheim Investigational Site
Chertsey, United Kingdom
1160.71.1745 Boehringer Ingelheim Investigational Site
County Armagh, United Kingdom
1160.71.1755 Boehringer Ingelheim Investigational Site
Kirkcaldy, Fife, United Kingdom
1160.71.1741 Boehringer Ingelheim Investigational Site
London, United Kingdom
1160.71.1742 Boehringer Ingelheim Investigational Site
Newcastle upon Tyne, United Kingdom
1160.71.1751 Boehringer Ingelheim Investigational Site
Newport, United Kingdom
1160.71.1752 Boehringer Ingelheim Investigational Site
Northampton, United Kingdom
1160.71.1743 Boehringer Ingelheim Investigational Site
Romford, Essex, United Kingdom
1160.71.1748 Boehringer Ingelheim Investigational Site
York, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00808067     History of Changes
Other Study ID Numbers: 1160.71, 2008-005248-17
Study First Received: December 12, 2008
Results First Received: December 20, 2013
Last Updated: June 3, 2014
Health Authority: Australia: Dept of Health and Ageing Therapeutic Goods Admin
Austria: Medicines and Medical Devices Agency
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Brazil: National Health Surveillance Agency
Bulgaria: Bulgarian Drug Agency, BG-1504 Sofia
Canada: Health Canada, Therapeutic Products Directorate
China: Food and Drug Administration
Czech Republic: State Institute for Drug Control (SUKL), CZ-100 41 Prague 10
Denmark: The Danish Medicines Agency
Finland: Finnish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Kurt-Georg-Kiesinger-Allee 3, D-53175 Bonn
Great Britain: MHRA
Greece: National Organization fo Medicines (EOF) National Ethics Committe
Hong Kong: Department of Health
Hungary: National Institute of Pharmacy (OGYI), H-1051 Budapest
India: Drug Control General of India
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: Ethics Committee
Korea, Republic of: Korea Food and Drug Administration (KFDA)
Malaysia: Drug Control Authority
Netherlands: Central Committee on Research Involving Human Subjects (CCMO)
Norway: Norwegian Medicines Agency (Statens Legemiddelverk)
Philippines: Bureau of Food and Drug
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Portugal: INFARMED I.P.
Romania: National Medicines Agency, Bucharest
Russia: Ministry of Health of the Russian Federation
Singapore: Health Sciences Authority
Slovakia: SUKL (state institute for drug control), SK-825 08 Bratislava 26
Sweden: Medical Products Agency Regional Ethics Committee of Uppsala
Switzerland: Swissmedic
Taiwan: Department of Health, Executive Yuan, Taiwan
Thailand: Thai Food & Drug Administration
United States: Food and Drug Administration

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Dabigatran
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anticoagulants
Hematologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 20, 2014